Search CORE

3 research outputs found

Safety of treatment with biologics for psoriasis in daily practice: 5-year data

Author: C van Weel
EMGJ de Jong
J B Boezeman
M Flendrie
MAM Berends
PCM van de Kerkhof
PPM Van Lümig
RJ Driessen
RJB Driessen
RV Patel
Publication venue: BioMed Central
Publication date: 01/01/2010
Field of study

Springer - Publisher Connector

Directory of Open Access Journals

Dose Reduction of the New Generation Biologics (IL-17 and IL-23 Inhibitors) in Psoriasis: a Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study, BeNeBio Study, Baseline Characterisctics

Author: Berends MAM.
Bovenschen HJ.
De Bruin-Weller MS.
De Jong EMGJ.
Dierckxens L.
Dodemont SRP.
Ghislain PD.
Hillary T.
Horvath B.
Lambert JLW.
Lanssens S.
Nikkels Arjen
Ossenkoppele PM.
Prens B.
Schots L.
Soenen R.
Temmerman L.
Van Den Reek JMPA
Van dER Schoots LS.
Van Der Voort EAM.
Van Doorn MBA.
Van Lümig PPM.
Van Riel CAM
Willaert F.
Publication venue
Publication date: 01/10/2023
Field of study

Open Repository and Bibliography - Liège

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

Author: A Boonen
AB Gottlieb
Aimee Readie
Alan Kivitz
Brian Porter
D Baeten
D Baeten
D Heijde van der
E Lubberts
Eva Dokoupilova
F Bosch Van den
F Wolfe
Hasan Tahir
IB McInnes
IB McInnes
J Braun
J Braun
J Braun
J Sieper
JH Duarte
K Kotsis
Karel Pavelka
LE Dean
Luminita Pricop
M Dougados
Marco Maradiaga
Mats Andersson
N Garg
PJ Mease
PPM Lümig Van
R Perez-Alvarez
RG Langley
Ricardo Blanco
S Ottaviani
SG Filler
W Hueber
Publication venue: 'Springer Science and Business Media LLC'
Publication date
Field of study

core

core